Penumbra (PEN) Free Cash Flow Growth (1y) (2015 - 2026)
Penumbra (PEN) Free Cash Flow Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 28.87% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 14.12% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 0.77% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 13.29% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 142.84% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -11.68% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 750.00% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 0.40% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -14.34% |
| 10 | Penumbra | 12.76 Bn | 12.10 Bn | 264.94 Mn | 10.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.81% |
| Mar 31, 2026 | 59.16% |
| Dec 31, 2025 | 80.90% |
| Sep 30, 2025 | 68.11% |
| Jun 30, 2025 | -2.48% |
| Mar 31, 2025 | 45.49% |
| Dec 31, 2024 | 25.81% |
| Sep 30, 2024 | 64.37% |
| Jun 30, 2024 | 3.81% |
| Mar 31, 2024 | 186.14% |
| Dec 31, 2023 | 145.97% |
| Sep 30, 2023 | 261.17% |
| Jun 30, 2023 | 139.57% |
| Mar 31, 2023 | 219.82% |
| Dec 31, 2022 | 157.71% |
| Sep 30, 2022 | -156.89% |
| Jun 30, 2022 | -2,729.97% |
| Mar 31, 2022 | 48.41% |
| Dec 31, 2021 | -1,198.07% |
| Sep 30, 2021 | 187.25% |